Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13730341 | 0.89 | JAK2 (0.53) | PDE4BPDE4DSYKCTSKCTSS | |
| Hydrochloric Acid SCHEMBL14880108 | 0.88 | JAK2 (0.52) | PDE4BPDE4DSYKCTSKCTSS | |
| SCHEMBL21914834 | 0.85 | CTSK (0.58) | PDE4BPDE4DSYKCTSKCTSS | |
| SCHEMBL1182188 | 0.84 | NFKB1 (0.58) | PDE4BPDE4DSYKCTSKCTSS | |
| SCHEMBL13086645 | 0.82 | PDE4B (0.45) | PDE4BPDE4DSYKCTSKCTSS | |
| SCHEMBL867999 | 0.81 | KCNH2 (0.58) | SYKABCG2KCNH2SCN5ASCN9A | |
| SCHEMBL13851414 | 0.81 | CYP2C19 (0.56) | PDE4BPDE4DCTSKCTSSABCG2 | |
| SCHEMBL21915358 | 0.79 | CTSK (0.54) | SYKCTSKCTSSABCG2ABCB1 | |
| SCHEMBL20511301 | 0.79 | TXN (0.63) | PDE4BPDE4DSYKCTSKCTSS | |
| SCHEMBL639631 | 0.79 | ABCB1 (0.48) | PDE4BPDE4DSYKCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598341-B2 | Process for etravirine intermediate and polymorphs of etravirine | HETERO RESEARCH FOUNDATION (IN) | 2013-12-03 | — | — | US | claimed |
| EP-2584901-A1 | A PROCESS FOR ETRA VIRINE INTERMEDIATE AND POLYMORPHS OF ETRAVIRINE | Hetero Research Foundation (IN) | 2013-05-01 | — | — | EP | claimed |
| US-20130096148-A1 | PROCESS FOR ETRAVIRINE INTERMEDIATE AND POLYMORPHS OF ETRAVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2013-04-18 | — | — | US | claimed |
| WO-2012001695-A1 | A PROCESS FOR ETRA VIRINE INTERMEDIATE AND POLYMORPHS OF ETRAVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2012-01-05 | — | — | WO | claimed |
| CN-110407756-B | Preparation method of 4- [ (4, 6-dichloro-2-pyrimidinyl) amino ] benzonitrile | 江西力田维康科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-110407756-B | Preparation method of 4- [ (4, 6-dichloro-2-pyrimidinyl) amino ] benzonitrile | 江西力田维康科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20150336900-A1 | Process for the Synthesis of Etravirine and Its Intermediates | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150336900-A1 | Process for the Synthesis of Etravirine and Its Intermediates | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2015-11-26 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| US-8809343-B2 | Pyrimidine derivative, preparation method and use thereof | FUDAN UNIVERSITY (CN) | 2014-08-19 | — | — | US | disclosed |
| WO-2014068588-A2 | PROCESS FOR THE SYNTHESIS OF ETRAVIRINE AND ITS INTERMEDIATES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2014-05-08 | — | — | WO | disclosed |
| US-20100121060-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-05-13 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| US-20090124644-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | TIBOTEC BVBA (BE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008080964-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | WO | disclosed |
| EP-1858861-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094930-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336900-A1 | Process for the Synthesis of Etravirine and Its Intermediates | CYP3A4, CYP3A5, ERN1 | PDE4B 2438/4885PDE4D 3258/4885SYK 4358/4885 |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | RTF2, MCM6, SAMHD1 | PDE4B 2998/4885PDE4D 3068/4885SYK 4673/4885 |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | CCR5, CTR9, NR1H3 | PDE4B 4442/4885PDE4D 4353/4885SYK 4347/4885 |
| US-20130096148-A1 | PROCESS FOR ETRAVIRINE INTERMEDIATE AND POLYMORPHS OF ETRAVIRINE | CYP3A4, CYP3A5, CYP4B1 | PDE4B 450/4885PDE4D 971/4885SYK 4555/4885 |
| US-20100121060-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | RTF2, MCM6, CDK6 | PDE4B 3018/4885PDE4D 3088/4885SYK 4787/4885 |
| US-20090124644-A1 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES | NR4A3, NR4A1, NR4A2 | PDE4B 1368/4885PDE4D 2146/4885SYK 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.